Home » Bami Oshinowo

Bami Oshinowo

Principal, Value, Access, and Pricing

Ms. Oshinowo leads engagement work within the Value, Access and Pricing Practice and drives the Early VAP & CP Centre of Excellence at CBPartners. Her primary expertise is on early-stage pipeline issues related to commercial strategy, including competitive positioning, pricing, market access and trial design optimization. Her geographical expertise includes the USA and EU where she routinely advises on business development and licensing decisions, as well as go / no-go pipeline advancement.

She has over 10 years’ experience in life sciences consulting where her work initially focused on generating payer insights for her clients, and then on the development of methods to incorporate physician insights in order to provide a more holistic approach to asset valuation.

Ms. Oshinowo holds an MSc in International Health Management from Imperial College London and a BSc (Hons) in Pharmacology from the University of Edinburgh.

Connect with Bami Oshinowo


+44 (0)7961 820 076


Published Articles

Novel Combinations: Double the Trouble

Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.

Strategic Thinking: The Global Drug Launch Pricing Dilemma

Several factors contribute towards manufacturers seeking new ways to develop global drug pricing strategies. Product launches vary based on geography; when comparing the USA to EU, access outcomes can vary significantly based on whether or not the pivotal trial design has been optimized for each region.

CBPartners Celebrates Over Two Years of Firm-Wide Women@CBP Events

Check out the firm-wide events that CBPartners' Women@CBP team has organized between 2017-2019. Here's to many more talks, socials, and cinema screenings!

Developing an Early Stage Biopharmaceutical Asset in Europe: Navigating Treacherous Waters

When biopharmaceutical products launch in the European Union, even experienced manufacturers can struggle to overcome the demanding standards of European payers. The complex market authorisation requirements and subsequent access decisions across 28 countries can lead to challenging timelines and confusing rollouts. Unfortunately for manufacturers, the future of European commercial planning is likely to become more challenging, as nations look to raise evidence standards and increase the scrutiny of pricing. Looking ahead over the next ten years, CBPartners is tracking many policy and payer trends which will affect the playing field for future launches. Examining these key trends in detail can provide further understanding of how manufacturers can create an “Early Asset Success Plan” for new products.

IWD 2018: Sustainable Consulting – Counteracting Push and Pull Factors for Women in Consulting

Women@CBP release insights about push and pull factors for women in consulting in celebration of International Women's Day 2018.